TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PReventing the EffectS of Intubation on DEglutition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* Required mechanical ventilation via an oral endotracheal tube~Exclusion Criteria:~* Unable to understand or speak English due to a language barrier~* Unable to understand or speak English due to a cognitive impairment~* Barium sulfate allergy~* Pregnancy~* Presence of any cardiac pacing device (including temporary epicardial pacing) without an underlying cardiac rhythm as confirmed by treating physician or diaphragmatic pacer~* Nasal endotracheal intubation during the present admission~* Patient is not expected to require ≥48 hours of intubation~* Pre-existing dysphagia/aspiration, voice or cognitive disorder~* Reflux with history of known or suspected aspiration~* Presence of a central nervous system, neuromuscular or connective tissue disease (e.g., stroke, Guillain-Barre, scleroderma)~* Active seizure disorder~* Pain disorder of the jaw muscles or mandibular joint~* Ever tracheotomy or prior endotracheal intubation other than for surgery (≤ 1 year)~* Head and/or neck disease (e.g., oropharyngeal cancer)~* Head and/or neck surgery other than tonsillectomy~* Known or suspected anatomical abnormalities or pre-intubation trauma of the oral cavity, pharynx, larynx, or esophagus~* Known or suspected sleep apnea (treated or untreated)~* Prior major thoracic surgery (e.g., sternotomy, thoracotomy)~* Unplanned (e.g., self- or accidental) extubation or re-intubation before consent~* Weight exceeds capacity of the radiology equipment~* Expected tracheostomy tube placement while in hospital~* Moribund (\>90% probability of mortality in hospital), based on ICU team's assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Exercise and sensory stimulation (Type: EXPERIMENTAL): 60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics in Radiation-treated Gynecologic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with cancer in the small pelvis and waiting to receive radiotherapy either as a primary or as a secondary treatment following surgery. Chemotherapy may or may not be part of the treatment regimen.~* Age, older than 18 years old.~* Agreement for participation in the study by signed written informed consent.~Exclusion Criteria:~* Previously treated with irradiation of the pelvic area.~* Reluctance to refrain from using other probiotic products during the participation in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): capsules containing corn starch
- Probiotic low dose (Type: ACTIVE_COMPARATOR): capsules containing probiotic powder and corn starch
- Probiotic high dose (Type: ACTIVE_COMPARATOR): capsules containing probiotic powder and corn starch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with atopic dermatitis by a Children's Hospital of Wisconsin (CHW) pediatric dermatologist~* Age 1- 18 years old~* Primary residence in Milwaukee County~Exclusion Criteria:~* Other chronic, systemic diseases other than asthma or environmental allergies~* Hyperimmunoglobulin E or Job syndrome~* Ichthyosis disorder other than ichthyosis vulgaris~* Prior systemic therapy or phototherapy for atopic dermatitis~* Ongoing or prior treatment for known Vitamin D deficiency~* On chronic systemic corticosteroids for asthma

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Atopic dermatitis (Type: None): Pediatric patients ages 1-18 years old with atopic dermatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* Diagnosis: single, cytology-proven papillary thyroid carcinoma measuring 1 cm or less in diameter (microcarcinoma, T1a), without visible extrathyroidal extension, and with negative central and lateral neck lymph nodes by ultrasound~Exclusion Criteria:~* Patient refusal to participate~* History of prior thyroid or parathyroid surgery~* Previous recurrent laryngeal nerve injury~* Inability to make decisions or comply with follow up~* Co-existing indication for thyroidectomy~* Aggressive cytological or molecular features~* Multifocal papillary thyroid carcinoma~* Pregnant or breast-feeding~* Anatomically unfavorable location of the tumor (proximity to recurrent laryngeal nerve or trachea)~* Documented or suspected distant metastasis~* History of radiation to neck or face~* Family history of thyroid cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- percutaneous ethanol ablation (Type: EXPERIMENTAL): The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brief Intervention Study for Quitting Smoking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smoker~* Age \> 18 years~* Motivation to quit smoking~Exclusion Criteria:~* severe somatic comorbidity or reduced life expectancy~* severe episode of a psychiatric disease~* reduced cognitive ability~* abuse of alcohol or illicit drugs~* other reasons at the discretion of responsible local study tutor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brief advice (Type: ACTIVE_COMPARATOR): A brief advice to stop smoking of about 10 min accompanied with self-help material
- Compact cessation course (Type: EXPERIMENTAL): Cessation intervention of 2 x 120 min in a group setting
- Standard cessation course (Type: ACTIVE_COMPARATOR): Cessation course in a group setting over 6 dates

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Two Anger Management Programs for Teens.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* self-, or allo-referred (parents, peers, court-ordered, school, etc.), based on their propensity for displaying various disruptive, externalizing behaviors, including, anger, hostility, oppositional behavior, and temper outbursts, and as such identified by Youth Services (YS) as a suitable candidate to attend a YS anger management program.~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Real Deal program for Anger Management (Type: ACTIVE_COMPARATOR): The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict.
- Mind-body Bridging program (Type: EXPERIMENTAL): The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to give written informed consent for participation in the study.~2. Clinical diagnosis of Amyotrophic Lateral Sclerosis (ALS).~3. Male or female patients between 18 to 80 years (inclusive).~4. Forced Vital Capacity (FVC) 65% of predicted value for gender, height and age at screening.~5. Evaluated with ALSFRS-R and Norris clinical rating scales for at least the past 4 weeks before study drug administration.~Exclusion criteria~1. Unable to understand information about the study or are expected not to collaborate with the study team.~2. Concurrent serious disease, other than ALS, at the discretion of the nvestigator.~3. Pregnancy.~4. Patients of childbearing potential not willing to use adequate double contraception with less than 1 percentage failure rate after the screening visit until the last visit.~5. Addiction to drugs or alcohol.~6. Confirmed HIV, hepatitis B or hepatitis C.~7. Known bleeding disorders or abnormal bleeding events.~8. Treatment with anticoagulant drugs warfarin and novel oral anticoagulants (NOAC) within the last 14 days prior to screening.~9. Treatment with Riluzole or Lamotrigine within the last 28 days prior to study drug administration.~10. Hypersensitivity to dextran sulfate.~11. Poor venous access.~12. Patients with clinically significant abnormal PK-INR, fibrinogen, von Willebrand factor and activated partial thromboplastin time (APTT) at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ILB (Type: EXPERIMENTAL): ILB treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Animal Assisted Therapy in Outpatient Psychiatry Clinics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient psychiatric patients of Dr. Matt Kern who meet the criteria to be diagnosed with Major Depressive Disorder and/or Generalized Anxiety Disorder via Patient Health Questionnaire (PHQ-9) and/or General Anxiety Disorder (GAD-7)~Exclusion Criteria:~* Prior history of animal related trauma~* Participants that require psychiatric hospitalization during the experiment will have their information excluded from analysis~* Participants who have changes made to any Hypertension / Blood Pressure medications during the experiment will have their Blood Pressure measurements removed from final analysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Animal assisted therapy cohort (Type: EXPERIMENTAL): This arm will be the group that is randomized to receiving animal assisted therapy during outpatient office visits.
- Control therapy cohort (Type: NO_INTERVENTION): This arm will be the group that will receive the standard outpatient psychiatric treatment without animal therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, ≥2 years of age and ≤17 years of age, of any race or ethnicity~* Must have clinical diagnosis of mild to moderate atopic dermatitis (AD) at both Screening and Baseline Visits, defined as IGA score of 2 or 3 (Hanifin and Rajka, Rothe 1980)~* Must have AD affecting ≥ 5% total body surface area (TBSA) at Baseline~* History of AD for at least 3 months prior to Baseline~* Informed consent/assent in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline (21 CFR §50.25\[c\]) and applicable regulations, before completing any study-related procedures~Exclusion Criteria:~* Use of topical corticosteroids within 7 days prior to Baseline~* Use of systemic corticosteroids, topical calcineurin inhibitors, photo-therapy (eg, PUVA, UVB) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to Baseline~* Subjects that require systemic therapy for the treatment of atopic dermatitis~* Use of systemic anti-infective or antibiotic treatment within 14 days prior to Baseline~* Subjects who present with clinical conditions other than AD that may interfere with the evaluation (eg, generalized erythroderma, acne, Netherton's Syndrome, psoriasis)~* Secondary infection of AD (bacterial, viral or fungal) within the skin area under study or open skin infections in any area at Baseline~* Women of childbearing potential who are lactating or pregnant as determined by urine pregnancy test at Screening. • History of MRX-6 cream 2% sensitivity or to any component of the test article~* History of severe anxiety and/or depression; any history of suicide attempt~* Subjects with a history of human immunodeficiency virus (HIV) as determined by medical history~* Subjects with any screening clinical laboratory result outside the normal range that is clinically relevant in the opinion of an appropriately qualified physician~* Subjects who, in the opinion of the Investigator, would be non compliant with the visit schedule or study procedures~* Participation in any other investigational trial within 6 weeks of Baseline, or during study conduct~* Chronic condition(s) which are either unstable or not adequately controlled~* Use of non-sedating anti-histamines within 7 days of first dose or at any time during study conduct~* Drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's ability to be compliant with study-related procedures

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): BID
- MRX-6 (Type: EXPERIMENTAL): BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided.~* Aged 18-75 years.~* Had completely resected pathological confirmed stage IIA-IIIA NSCLC.~* EGFR activating mutation in exon 19 or 21.~* Had completed four cycles of platinum-based adjuvant chemotherapy.~* Able to start the investigational therapy within 4 weeks after the completion of four cycles of adjuvant chemotherapy.~* ECOG performance status of 0-1.~* Had a life expectancy of 12 weeks or more.~* Adequate hematological function, adequate liver function and renal function.~* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.~* Female patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test.~Exclusion Criteria:~* Had had previous chemotherapy besides four cycles of adjuvant chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).~* Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder.~* Any evidence confirmed tumor recurrence before investigational therapy.~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of clinically active interstitial lung disease.~* Eye inflammation not fully controlled or conditions predisposing the subject to this.~* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).~* Known human immunodeficiency virus (HIV) infection.~* Pregnancy or breast-feeding women.~* Ingredients mixed with small cell lung cancer patients.~* History of neurologic or psychiatric disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 6-month icotinib (Type: EXPERIMENTAL): Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
- 12-month icotinib (Type: EXPERIMENTAL): Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
- Chemotherapy alone (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact on the Nitrogen Balance, Autonomy, Safety and Tolerance of Enteral Diets Made of With Nutrilon Without Lactose® Fortified by Concentration Versus by Maltodextrin and Oil Supplementation,After Surgery for Congenital Heart Disease, in Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children from 0 to 2 years undergoing cardiac surgery (corrective or palliative) for congenital heart surgery, with or without extracorporeal circulation~* Expected stay of 5 days in PICU after surgery~* Expected need of invasive ventilation for 48h after surgery~* Expected need for enteral feeding during 5 days.~* Obtaining the informed consent of the child's legal guardian after being informed of the goals, benefits and potential risks of this study~Exclusion Criteria:~* Medical indications for specific diet~* ECMO~* Dialysis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- Study Diet (Type: EXPERIMENTAL): Enteral diet made of Nutrilon without lactose® fortified by concentration
- Control Diet (Type: ACTIVE_COMPARATOR): Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: H1N1 Vaccine in Pregnancy: a Registry for the Fall and Winter of 2009

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Received the H1N1 vaccine during pregnancy~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues